MDGN 205
Alternative Names: Glucagon-like peptide-2 gene therapy - Medgenics; MDGN-205; TARGTGLP-2™Latest Information Update: 30 Aug 2021
At a glance
- Originator Medgenics
- Developer Avalo Therapeutics
- Class Gene therapies; Peptides
- Mechanism of Action Glucagon-like peptide 2 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Short bowel syndrome
Most Recent Events
- 26 Aug 2021 Cerecor is now called Avalo Therapeutics
- 03 Feb 2020 Aevi Genomic Medicine has been acquired and merged into Cerecor
- 28 Dec 2018 No recent reports of development identified for preclinical development in Short-bowel-syndrome in USA (SC, Implant)